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Interaction of Coagulation F actors
}IC. HEMKER
Medical Faculty Maastricht, Department of Biochemistry, Biomedical Centre,
Beeldsnijdersdreef 1 0 1, Maasfiicht (The N etherlands)
1. INTRODUCTION
The interaction of coagulation factors is an exciting yet poorly studied
field in enzymology. Its charm lies in the unique ensemble of enzymatic
actions comprised in the reaction mechanism of blood coagulation. On the
one hand, it shows beautiful examples of welldocumented modes of inter-
action of proteins such as limited proteolysis. On the other, it appears that in
blood coagulation some ways of protein interaction occur that are hardly
known in other fields of biochemistry. Coagulation shows feattues that can
only be explained when essentially novel mechanisms of protein-protein
interaction and of protein-lipid interaction are recognised.
Still, a description of the coagulation process as the sum of its dissected
parhs hardly does justice to the beauty and intricate refinement of the whole.
The constitutive reactions are qualitatively so interbwined and quantitatively
so economically patterned and well-balanced that the whole is, as a result, a
unique non-linear kinetic system. This system joins the seemingly incom-
patible properties of immediate explosive kinetics on the one hand, and
self-limiting properties on the other. In this way coagulation meets the very
strict demands of no leakage from wounded vessels and no thrombosis in
intact vessels. Failure to meet these demands is a major drawback in the
struggle for survival. Clearly the physiology of vessels and platelets is as
important here as coagulation. Yet it must be recognised that thrombin plays
a key role in these fields [49,60,63] . Therefore the study of the coagulation
mechanism is by no means just the study of the generation of a fibrin clot.
Insight into the mechanisrrr- of thrombin generation is essential for an
understanding of the processes of haemostasis and thrombosis. The anti-
haemophilic factors play a central role in thrombinogenesis.
It must be borne in mind that it is not only at the level of thrombin that
coagulation interacts with other important physiological systems. Factor-XII
(Hageman factor) activation not only triggers off intrinsic coagulation, but
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Fig. 1. An artist's view on the interaction of blood coagulation factors' After an original
drawing by Leo Vroman.
appears to play a role in the kinin system, the complement system and in
fibrinolysis as well 17,40,52,54,657 .
Given the medicat importance of haemorrhage and thrombosis 
- more
than half of all deaths ueing caused or complicated by either 
- the study of
the interaction of blood coagulation factors imposes itself as a medical neces-
sity. But even if it did not, the study would still be fully justified on bio-
chlmical grounds. Conditions in coagulating plasma differ essentially from
those prevailing in enzymatic systems studied in the laboratory. This neces-
sitates'a reappiaisal of the basic notions employed in enzymology: a whole-
some exerciie tor the biochemist who gets entangled in this field [26] '
2. DEFINITIONS AND BASIC NOTIONS
To avoid confusion it seems advisable to begin with a definition of some
seemingly well-known terms U,1-2l '
6n iizyme is a protein with catalytic properties capable of converting
some molecule (in coagulation always another protein) by changing covalent
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bonds. In coagulation enzymes always break bonds: the coagulation factors
with enzymatic properties are proteolytic enzymes. Factor XIII. off the
main coagulation pathway is the only exception.
Enzymes convert a substrate into a product.In coagulation the substrate
is often a proenzyme and the product itself is then an enzyme. It is therefore
confusing to speak of any factor as a substrate or as an enzyme unless the
reaction in which it plays such a role is clearly defined. Most coagulation
factors are substrates in one reaction and enzymes in another.
In coagulation the term 'substrate' is used in still another way. It is some-
times said that, say, the factor-vlll activity of some preparation is tested
rsing a factor-Vlll deficient substrate. This means that the factor-Vlll defi-
cient plasma is used as a reagenf for factor-vlll activity, i.e., to constitute a
reaction mixture in which clotting time depends upon the concentration of
factor VIII.
These definitions of enzyme and substrate are current in general enzy-
mology. This does not automatically imply that the kinetics of substrate
conversion will be those known from the textbooks. The kinetics developed
in general enzymology presuppose conditions not necessarily prevailing in
blood coagulation experiments. Examples are the assumption of excess of
substrate over enzyme and the measuring of initial reaction velocities. Some
notions from regular kinetics remain useful.
The Michaelis constant (K- ) is defined as the concentration of a reactant
at which half the maximal reaction velocity is obtained. Maximal reaction
uelocity (V-"*) is the reaction velocity that would be obtained at an in-
finite concentration of the varying reactants in a given reaction mixture (i.e.,
at a fixed concentration of the other reactants). In coagulation, the reactant
for which the K- can be defined may be the enzyme as well as the substrate
1261.
The conversion of a proenzyme into an enzyme will be called actiuation.
When the proenzyme is a coagulation factor (indicated by a roman numeral)
the activated factor will be indicated by the subscript a (e.g.thrombin =
factor II. ).
Some factors (e.g. factors V and VIII) can have their activity enhanced
Fig. 2. Basic graphs in enzyme kinetics. The concentration (c) in coagulation can be
substrate or enzyme concentration. Meaning of the intercepts A, Vma*i B, lz V^o; C,
KmiD,  - ! lKm;E,7 lv " , ' ' o . .
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\l-lthout obtaining enzymatic properties. This will be called enhancement and
ir-rdicated by the subscript e. Finally the inactivated factors rvill be given the
subscript i.
3, CLASSIFICATION OF INTERACTIONS
The ground for aII enzymatic activity is that the stereochemtcal structure
of amino acid side-chains of the enzyme protein at one ctrcumscrilted place
in the molecule allows the substrate to bind and undergo changes that are
very unlikely in free solution. The site where the substrate binds and is
converted into product is called the actiue site of the enzyme.
The structure of the active site is determined not only by the presence of
specific side-chains but also by the particular juxtaposition of these residues.
This juxtaposition is in turn determined by the whole of the tertiary struc-
ture of the enzyme and will change with conformational changes on the part
of the enzyme, The generation of enzymatic activity in a previously inactive
protein molecule occuls because a conformational change in the protein
causes some side-chains to move and to attain the structure that forms the
active site (for a review see ref. 32).
such changes are best documented in proteins from the chymotrypsino-
gen group. Chymotrypsinogen is a protein containing the essential residues
for forming an active proteolytic centre in an unfavourable configuration'
When a specific covalent bond in this molecule is split, the previously stable
tertiary structure becomes unstable and changes to a new one. Now some
defined residues do constitute an active centre capable of proteolytic and
esterolytic activity. Among the active residues the major role is played by a
seryl group (hence the name 'serine esterase' for this group of enzymes) in
close cooperation with two histidyls. It is important to realise that in the
conversion from zymogen into enzyme there exists a transient state of the
molecule in which the covalent bonds are already broken while the enzy-
matically active tertiary structure is not yet attained: it is thus essentially a
change in tertiary structure that causes enzymatic activity. It is therefore
possible that changes in tertiary structure alone, not involving the breaking
of covalent bonds are able to generate enzymes. This indeed is encountered
in blood coagulation - and as yet hardly anywhere else. Hence the distinc-
tion in the following pa.raglaphs between activation resulting from conforma-
tional changes and activation by limited proteolysis.
The proteotytic activity of enzymes like chymotrypsin is not very specific,
and the same is true of its esterolytic activity. This is in marked contrast to
the enzymes in blood coagulation which from hundreds of surrounding
molecules often pick only the particular one that fits in the coagulation
pathway. This can hardly be achieved by specificity of the active centre
alone. Discrimination on the part of the active centre is limited to structures
of the order of magnitude of the active centte, say of 15 A diameter. The
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specificity required in brood coagulation concerns protein molecules andthus requires binding sites of the orler of m4gnitud" oilOlr S0 A; accessorybinding groups are therefore necessary. rne htter are in part located onproteins other than the enzyme itself. proteins adsorbJ next to the enzymeat a phospholipid-water interphase provide these sites. We call them para-enzymes [24]. Together with the protein carrying the active site they formcomplex enzymes. Hence p*ugrupfi b.
The paraenzymes^und"rgo 
"r,u.rges in activity induced by thrombin dis_cussed in paragraph 6.
Inhibitory reactions - important though rather neglected until now - arethe subject of paragraph z and a preliminary glimpse of the mechanism func-tioning as a whole is offered in thl hst paragraph.
4. ACTIVATION OF PROENZYMES
(a ) Limited proteoly sis
The best documented exampre in brood coaguration of activation by
Iratt^"9 proteolysis is the conversion of prothrombin into thrombin[20,35,45,47,57]. It wilr be briefly summarized here because it probabry is agood model for other activations occurring i" .ous"rutiorr, iotably for thatof factor IX.
Prothrombin is a single-chain protein with a morecular weight of 78 000.This.chain has four parts tentativlly calredA-Fragment, n-rrug-"rrt, Throm-bin-A chain and rhrombin-B chain. we adopt,ie nomenclui,rr" of Magnus-son here [45].
During activation the amino acid chain is cleft and the parts are separated.
T.h". t - and B-Fragments remain attached to each other by means of adizulphide bridge. E1:h 9f _ the four parts has a specific function. TheA-Fragment contains the ca-binding sites that via C"t;ii-p"othrombin to a
. A FRAqMENT 156 NEOpRoTHROl,4Bil i_S 426 t
A la .^u  Scr .
€#flts+%
1""' 
"'"" 
" ' i
Fig' 3. The breakdown of prothrombin (after Magnusson, ref. 4b), The numbers refer toamino acid residues' The arrow indicates the actiie ,"rirr", irr" ,qirrggr" the ca2+binding
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phospholipid-water interphase IL4,36,58,741. This is an essential feature of
the activation mechanism, as we shall see below.
The B-Fragment shows an affinity to factor V [34]. The Thrombin-A
Chain shows no homologies to known esterases but probably plays a role
in determining the specificity of thrombin. The Thrombin-B Chain contains
the active serine and histidines and also in other respects shows extensive
homologies with chymotrypsin, trypsin, elastase and other known serine
esterases [19]. The breaking of the bonds between the Thrombin-A Chain
and the Thrombin-B Chain induces in the Thrombin-ts Chain the confor-
mational changes that lead to the formation of an active centre. The Ca-
binding sites in the A-Fragment are 7-glutamyl carboxylic acids [75]. They
are not built into the protein during ribosomal synthesis 177,721. The
product of ribosomal synthesis is a precursor protein with pairs of ordinary
glutamic acid residues in the A-Fragment part. By a postribosomal vitamin
K-dependent step glutamic acid residues are modified into 7-glutamyl car-
boxylic acid residues. In the absence of vitamin K or during administration
of Vitamin K antagonists the precursor enters the blood where it can be
recognized as the so-called PIVKA-II (Protein Induced by Vitamin K Ab-
sence analogous to Factor II) [31].
There are extensive homologies between the coagulation factors II, VII,
IX, and X [15,16,45]. All four of them are synthesized as precursors that
need finalization in a vitamin K-dependent step. All four are serine esterases
but with distinctly different active sites, as can be inferred from their differ-
ent susceptibilities to different serine esterase inhibitors [43].
Factor II differs from the other three in that in its active form it does not
have the Ca2* binding groups of the A-Fragment. These groups are essential
for the functioning of factors VII., IX,, and Xu [36,58]. After activation of
these factors the part homologous to the A-Fragment thus remains attached
to the part comparable to the Thrombin-B Chain.
This is illustrated in Fig. 4. This figure should not be taken to indicate
FACTOR II
-S-S
E- FACTOR X
FACTOR IX
FACToR IXa
- e - c  -
-J ---
Fig.4. Analogies between clotting proteases (after Magnusson, ref. 45). The arrows indi-
cate the active serine (bold: activated; small: not activated). The squiggle is the Ca2+
binding site.
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that one proenzyme can give rise to either thrombin or to factor VII", IX'
or Xa. This suggestion, which may be found in the older literature [69], is
no longer tenable as each proenzyme (factor) together with its precursor
(PIVKA) has clear-cut immunological identity and because, as stated above,
the enzymes show distinct differences in their active sites [66] .
Of particular interest in the present context is the activation of factor IX.
Data on the details of the reaction in this particular factor are scarce. As yet
there are no reasons to assume that it differs considerably from the general
scheme outlined above [15,]-6]. The activating enzyme in the case of factor
IX is the product of the interaction of factors XII and XI. It has been
claimed that both factors engage in proteolytic and esterolytic activity. De-
tailed information as to the nature of the factor lX-activating enzyme is
conflicting 18,L7,39,4I,44,551 .
( b ) Actiuation without pro teoly sis
As outlined above, the essential feature of the conversion of a proenzyme
into an enzyme is the change of tertiary structure bringing about the correct
juxtaposition of the amino acid residues in the active centre. Splitting-off a
part from the amino acid chain is not the only way in which the tertiary
structure may be influenced. When a protein adsorbs onto an interphase its
tertiary structure changes. In factor XII this results in the formation of an
active centre.
The desorbed protein seems to retain its activity for some time, such
retention being due to complex formation of factor XII" with factor XI
[L7,73]. Another school claims however that factor XI activated by factor
XII" is itself a serine esterase [41]. The exact nature of the active product(contact product: C.P.) that results from the interaction of factors XII and
XI and a wettable surface does not appear to be determined.
A very interesting feature of coagulation is the activation resulting from
complex formation between two proteins. This has been most clearly shown
with reference to the interaction between prothrombin and staphylocoagu-
lase. The product of this reaction has a molecular weight and an amino acid
composition equal to the sum of the two proteins involved and has the
N-terminal amino acids of these proteins. The kinetics of its formation show
that one molecule of prothrombin and one molecule of staphylocoagulase
react to form one molecule of active product [22].
A comparable situation appears to exist with respect to streptokinase and
plasminogen, although here the situation is less clear because normal plasmin
is produced in addition to an active complex [77]. But it is clear in any case
that in coagulation interaction between proteins can cause the formation of
an active centre without the breaking of covalent bonds.
5. COMPLEX ENZYMES AT INTERPHASES
Phospholipid micelles participate in the coagulation reaction sequence by
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offering a phospholipid-water interphase to the interacting coagulation fac-
tors.
Again the best documented interactions are to be found in the final steps
of the coagulation pathway, i.e., the interaction of the factors v", X,, and II
12,9,L4,18,23,28,30,581. It has been shown that these three proteins all
bind to the interphase. Both factor II and factor X, possess ?-carboxyglu-
tamyl residues that via ca2 * presumably bind to anionic sites at the inter-
phase. This may partly explain the correlation between the charge of the
micelles and their thromboplastic activity. Model studies of factor V with
hydrophobic powders make it probable that factor v binds to phospholipid
interphases by hydrophobic interaction [38]. The fact that micelles from
homogeneous phospholipids are much less active in coagulation than mixed
ones may be due to the generation of favourable mosaic pattems of hydro-
philic and hydrophobic patches in the latter case [24]. The kinetics of the
formation of prothrombinase support the hypothesis that one molecule of
factor X" absorbed next to one molecule of factor v forms one molecular
unit fit for prothrombin conversion [23]. Prothrombin will fit into this
complex by binding to the phospholipid with its A-Fragment and to factor v
with its B-Fragment. This fixation probably reduces freedom of movement in
the vulnerable sites of the prothrombin relative to the active site of factor
X", thus enhancing the efficiency of factor X, action. Factor X, in free
solutions can also activate factor II but at a pace of less than lvo of that of
the equivalent amount of prothrombinase complex [42] .
The interaction between the factors vIII" and IX, and phospholipid mi-
celles that form the factor-X activating enzyme is again much less well
known than the generation of prothrombinase. yet evidence has been pre-
sented that the antihaemophilic factors interact in a way precisely analogous
to that described for the factors X. and v", and that they form a factor-X
activating enzyme in this way [28,33,56]. If this is true, the factors IX.,
vIII" and X form a trimolecular complex at the interphase, from which
factor X" results.
Fig. 5. Prothrombin and prothrombinase at a water-lipid interphase.
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It may even be the case that factor X" does not detach from the surfacebut directly complexes with factor v" t; form the prothrombinase moietydescribed above. This is the more likely as proteins Ldsorbed onto a lipid:
water interphase retain a fair degree of freedom of movement in the plane ofthe interphase [78].
It is clear that direct measurement of proteins adsorbed onto interphases,
e'g' by ellipsometry, is of prime importance for the further studying oi tt 
"r"phenomena [50].
6. ENHANCEMENT
No enzymatic actions of factors v and vIII have been demonstrated.They appear to function only as paraenzymes to the factors X. and IX.. yet
some kind of activation of these factors does take place. The activity of bothfactors is markedly enhanced by a low concentration of thrombin
L4,5r,62,64'1. Yet, in the strict sense no enzymatically active centre isf91med in these proteins. we therefore propose the term enhancement forthis type of activation. In symbols: v becomes vu and vIII becomes vIII".The nature of the enhancement of factor vIII is iot yet clear. More details
are known about factor v that again may be of use as I model although heretoo much is uncertain.
It has been shown [11,98] that human factor v exists in a 4g0 000 mol.
wt. form that can spontaneously convert into a 120 000 mol. wt. form. Thishas been interpreted in terms of the splitting of a tetramer which presumabry
is reversible. Thrombin and a fraction from Russell's viper venom brin-g
about an irreversible transition into the low molecular-w"igt t for-. Giventheir nature one wourd expect such enzymes to act by rimited proteolysis.
Indeed small molecular-weight differences between factor v treated withthrombin and untreated factor V have been reported [].11.Such activation appears not to be essential for factor V to function in the
coagulation system. It is, however, essential for the functioning of factorVIII [64]. The form of factor V with enhanced activity is much more labilethan the untreated form, and the thrombin-treated form even more so thanthe RVV-treated one. It has been shown that the inactivation of factor v
results from the reaction of two molecules of factor v" t2g]. This leads tothe following scheme:
factor v + 2 factor u thrombin or RVV 2 factor v" + factor vi
Although the subunit structure of factor vIII is currenily a matter of
considerable interest, it can be seen elsewhere in this book that the role ofthese subunits in the coagulation mechanism and the exact nature of the
action of thrombin are still obscure.
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XI I  +  X I  .+  CoNTACT PRoDUCT
i
I X  +  I X a  V I l l "  -  Y 1 1 1
I X a  +  V I I I e  +  P . l i p  +  C a + +  +  T E N A S E  :
X a ,  V e  +  P . l i p  +  C a - -  - P R 0 T H R 0 M B I N A S E
pRoTHRoMBIN 
-Ya,  1Hggt4g1x  i "  
'
Fig. 6. A biochemist's view of the interaction of clotting factors. The roman figures
indicate the corresponding coagulat ion factors. P.l ip.,  phospholipid. Only the intr insic
pathway is shown.
A scheme of the various interactions that give rise to thrombin formation
via the intrinsic pathway is given in Fig. 6.
7. INHIBITORY REACTIONS
The serine esterases among the coagulation factors II., VIIa,IXu, and Xu
all seem to interact with antithrombin 3 although for some factors (IIu and
X.) this has been shown more definitely than forothers [3,10,13,79]. Fac-
tor XI" is also reported to be inactivated by antithrombin 3 [68].
Such inhibiting reactions are exhemely important features of the coagula-
tion system. A 50% reduction of antithrombin 3 leads to a pronounced
tendency to thrombosis [48], and complete absence is not encountered
possibly because it is a lethal mutation.
c2 -Macroglobulin and 1-antitrypsin also inhibit active coagulation factors
t671 .
Other inactivation mechanisms exist as well. We already mentioned the
spontaneous dimerisation of enhanced factor V to an inactive product.
Thrombin thus leads to a burst of relatively short-lived activity on the part
of factors V and VIII. This is one of the features that determines the non-
linear character of the coagulation mechanism (see below).
Still another type of inhibiting reaction may result from the generation of
breakdown products of proenzymes (i.e., factors II, VII, IX and X). An
inhibitory activity has been ascribed to the A- and B-Fragments of prothrom-
bin [46]. Whether this is a novel activity on the part of these polypeptides
or simply a cause of their affinity for phospholipids and factor V is as yet
unclear.
A final group of reactions inhibiting the coagulation process is the break-
down of many factors by plasmin. Apart from fibrin, at least factors II, V,
and VIII are consumed by plasmin. The coagulation-inhibiting action on the
part of excess phospholipid can be simply explained by the fact that an
increase of the surface of the phospholipid-water interphase reduces the
chance for the interacting coagulation factors to meet. Apart from that,
v - . i -  vx l * x a
4t
some types of phospholipids - such as can be isolated from bovine brain -appe'r to have an.inhibiting action per se Ib,6] . e*"r,.r-unty ttrev inninii nvprovoking adsorption of the coaguration factors in a steric mode that doesnot generate an active complex- The same type of explanation has beenproposed for the inhibitory action of poryene u"iiuioiio-iort 
.
8. COAGULATION AS A NON.LINEAR SYSTEM
Even if complete, the above qualitative sketch of the possible interactionsof coagulation factors would not represent an exhaustive description of thecoagulation system. For such a description must take into account thekinetics of the system, the more so because brood coagulation belongs to theset of systems that are compricated enough to show" non_linear behaviour.This means that in these systems there exists a varying relationship betweenthe change of some parameter (say, substrate concen"tration) and its effect(say, reaction velocity).
In simple systems an increase in substrate concentration (or a decrease ininhibitor concentration or an increase in enzyme concentration) will alwayscause an increase in reaction verocity. In non-line* ,y.i"-, this is not thecase.
Non-linear behaviour is expected on a theoretical basis and is indeed ob-served in biochemical systems that exc-eed a certain dd;; of complexity.For a general view of the field see ref. 27 . sel,kov ;"r' gt;;; a review of thesystems that are comprex enough in principle to show th"is type of behaviour[70]. one of them is shown in Fig. T, wheie E is the 
"nryi"that converts Xinto Y. E is activated by row concentrations of y and inhibited by a highconcentration of Y. y is converted into y' in a second reaction. It takes ritileimagination to project this scheme onto a part of the coagulation mechanism
as is shown also in Fig. T.
As we know, thrombin first enhances and then destroys factor-v activity.The product of prothrombinase activity thus both activates and inactivatesits enzyme. we see that even a small subsystem of coagulation already satis-fies the condition for a nonJinear system; and therel, ,ro doubt that thecomplete system will have a complicaied non-linear character.
er. ]
rnorHnouermsef.". t . .  ANTTTHRoMBIN
pR9THR9MBTN . 
+'i|j,lorgln --\,METATHRoMBTN
,T3;* " 
non-linear kinetic mechanism and its projeetion on part of the coagulation
l
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On experimental grounds, too, there can be no doubt as to the non-linear
character of the coagulation system. The most characteristic feature of
coagulation is that the all-or-none chemical kinetics combine with a limited
spatial extent of these changes. When studying coagulation in vitro one is
inclined to forget that effective in vivo coagulation is limited to a confined
region in space. Coagulation in vivo is a limited explosion, i.e., an explosive
change that sets its own boundaries. With certain precautions this can be
readily imitated in vitro [21]. The importance of the phenomenon is clear.
Thrombogenesis is the result of thrombin formation beyond healthy limits
and a haemorrhagic tendency is the failure to produce a sufficiently impor'
tant "thrombus" at a bleeding site. I will not go into the details necessary to
apply this reasoning to platelets and vessels as well. Suffice it to say that
thrombin is a necessary reactant to make irreversible platelet thrombi (or, as
the case may be, hemostatic plugs). Given the scope of this chapter I shall
not deal with these more complex topics here, however consistent with the
foregoing general scheme it would be to do so.
The explanation of the "limited explosion" must be sought in a combina-
tion of non-linear kinetics and physical transport phenomena such as bulk
stream and diffusion. Again we will simplify matters by considering only
diffusion as a physical mechanism for the introduction of concentration
gradients.
Non-linear systems have fascinating kinetic properties including multiple
steady states, excitation thresholds, spontaneous generation of dissipative
structures, memories, all- or- none behaviour, etc. A combination of an
excitation threshold, multiple steady states and a diffusion gradient makes it
possible for a "limited explosion" to occur.
(a) Excitation threshold
Usually a system in a steady state will react to a change in the environ-
ment (perturbation) by finding a neighbouring steady state. Non-linear sys-
tems may show the same behaviour, but when a perturbation exceeds a
certain threshold unexpected behaviour will result (Fig. 8).
Fig. 8. Perturbation in a non-linear system. (A) below the excitation threshold. (B) above
the excitation threshold.
t)
c
0
o
t i m e
43
(b) trIultiple stead-r' states
\\-hen a s!'stem shows non-linear kinetics, and the velocity of generation of
the subsrrate by an independent system decreases with increasing substrate
concentrarion (as in the case of simple equilibrium), the situation depicted in
Fig. 9 resu-lts.
At three concentrations the velocity of formation equals the velocity of
breakdown (a, b, and c), so that here the system will be in a steady state.
These steady states will be stable in the points a and b only. In these points
but not in c small perturbations in the concentrations tend to be damped
out (see further ref. 70). Large perturbations in the concentration tend to
carry the system from one steady state into another. In combination with
the mechanism discussed under (1) a perturbation of sufficient size to ex-
ceed the threshold may cause a deviation from concentration that is suffi
cient to put the system in an other steady state.
when the perturbation is itself a concentration change of some reactant -
as in coagulation it is very likely to be - not only the time of exposure to
the perturbation will be important, but also its magnitude.
one can imagine how from the site of a lesion - either a wound or an
atheromatous plaque - a chemical signal diffuses into the surroundings. At
places near the lesion the concentration will be above the threshold that
causes a coagulum or a thrombus, and further from the lesion the concentra-
tion will drop below that threshold. Thus three general factors influence the
size of the coagulum: (a) The power of the source of the procoagulant. This
in turn will depend upon the nature of the lesion and the procoagulant
potency of the blood. (b) The potency of the anticoagulants. (c) The shape
of the gradient of the chemical signal. This is not only influenced by diffu-
sion constants but also by the flow and shape of the vessels (Fig. 10).
Again it must be stressed that this description offers only a general view
and does not pretend to be complete. In fact the same mechanism will come
c o n c .
Fig, 9. Multiple steady states in a non-linear system. a and b, stable steady states; c,
unstable steady state; conc., concentration; vel., reaction velocity.
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Fig. 10. General factors determining the extent of a limited explosion. Drawn line,
gradient of the chemical signal. Dashed line, excitation threshold. a, extent of the "explo-
s ion" .
into play more often. one can imagine for instance: (a) The enzyme contact
product diffusing from a "contact" source and acting upon factor IX while
factor IX. is inactivated by antithrombin 3. (b) ADP diffusing from a local-
ized ATPase in a wound, triggering thrombocytes and being coverted into
AMP. (c) Thrombin generated at and diffusing from a thromboplastic site,
etc.
As we did in the qualitative part of this chapter, here again we stress only
general principles. Clearly the kinetic description of the thrombin-generating
system is still in its infancy. we can do no more than indicate a few of the
complications that are likely to be encountered in determining the interac-
tion of coagulation factors, and stress the need for an increasingly more
detailed description.
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